Magnesium Supplementation in the Second Trimester of Pregnancy to Overweight and Obese Individuals
Magnesium Supplementation in the Second Trimester of Pregnancy for Overweight Individuals
This is a prospective, randomized, placebo controlled study with three parallel arms examining the effects of magnesium supplementation in the second trimester of pregnancy.
Recent research has shown that supplemental magnesium can have beneficial effects, especially in overweight individuals. Not only do many people have a magnesium deficient diet, there is also evidence that magnesium can improve blood sugar levels. Due to the growing concern of obesity with pregnancy and its associated complications, such as diabetes and abnormal fetal growth, magnesium therapy could have novel and beneficial effects on pregnancy outcomes.
In this study, 60 overweight and obese pregnant patients in their first trimester will be enrolled and randomized. The first group (A) will receive oral magnesium citrate (300mg elemental Magnesium), group B will receive dietary counseling about following a magnesium rich diet from a nutritionist, and group C will receive a placebo (control). Blood and urine specimens will be collected at three time points during the pregnancy to analyze changes in levels of metabolic markers, inflammatory markers, and protein expression profiles. Fetal and maternal complications of pregnancy will be noted, including maternal weight gain. At delivery, patients will have a placental cord blood specimen and placental biopsy collected for gene expression patterns and further analysis.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
California
-
Westwood, California, États-Unis, 90095
- 200 Medical Plaza UCLA Ob/Gyn Clinic
-
Westwood, California, États-Unis, 90095
- West Medical UCLA Ob/Gyn Clinic
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Between 18 and 40 years of age
- Pregnant in the first trimester
- Able to give informed consent
- Planning to deliver at UCLA
- BMI greater than or equal to 25
Exclusion Criteria:
- On insulin therapy or other oral hypoglycemic agents
- Multiple gestation
- Baseline HgbA1C > 6.5%
- Prior history of clinically diagnosed T2D
- Multiple dietary restrictions/food allergies
- Heart, renal, or liver failure
- Clinical history of psychiatric illness or substance abuse
- Out of town travel planned at study visits
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Magnesium Supplement
Magnesium citrate dietary supplement (300 mg elemental Magnesium daily dose) given week 13 to week 28 (two pills daily)
|
Magnesium citrate tablets 950 mg, two pills once daily (Total daily dose of 300 mg elemental magnesium)
|
|
Comparateur placebo: Placebo
Identical appearing pill with inactive ingredients given week 13 to week 28 (two pills daily)
|
Identical appearing placebo with inactive ingredients, two pills once daily.
|
|
Comparateur actif: Diet
Nutritionist counseling session and advice on following a magnesium rich diet from week 13 to week 28
|
Nutritionist counseling session and advice on following a magnesium rich diet
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in maternal biomarkers during pregnancy up to 28 weeks
Délai: up to 28 weeks
|
Blood and urine markers of inflammatory and metabolic markers will be assessed during the pregnancy,comparing baseline values to second trimester values, which will be up to 28 weeks.
|
up to 28 weeks
|
|
Neonatal birth weight/height
Délai: Up to 10 months
|
This measure will be assessed at neonatal delivery, which will occur at a maximum of up to 10 months from randomization.
Neonatal weight and height at birth will be assessed.
|
Up to 10 months
|
|
Change in maternal biomarkers in pregnancy in the third trimester
Délai: Up to 36 weeks
|
Blood and urine markers of inflammatory and metabolic markers will be assessed during the pregnancy,comparing baseline values to third trimester values, which will be up to 36 weeks.
|
Up to 36 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Neonatal outcomes
Délai: Up to 10 months
|
This measure will be assessed at neonatal delivery, which will occur at a maximum of up to 10 months from randomization. At delivery, neonatal characteristics will be assessed: Macrosomia, preterm birth, head circumference, and apgar score. |
Up to 10 months
|
|
Neonatal tertiary outcomes
Délai: Up to 10 months
|
This measure will be assessed at neonatal delivery, which will occur at a maximum of up to 10 months from randomization.
Cord blood and placenta will be collected at delivery, and we will examine endothelial progenitor cell presence in cord blood, PON expression in cord blood, and DNA expression from the placental tissue.
|
Up to 10 months
|
|
Pregnancy complications
Délai: Up to 10 months
|
From date of randomization until the date of delivery of the neonate, up to a maximum of 10 months, pregnancy complications such as development of gestational diabetes, hypertension, proteinuria, shoulder dystocia, cesarean section, as well as amount of weight gain will be assessed from the chart.
|
Up to 10 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Simin Liu, MD, ScD, MS, MPH, University of California, Los Angeles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Magnesium123
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Magnesium citrate
-
Relox Medical, LLCComplétéAccident vasculaire cérébralÉtats-Unis
-
Christopher BellRecrutementPerformances physiques | Intestin - Microbiote | Fonction mitochondrialeÉtats-Unis
-
Instituto Mexicano del Seguro SocialComplété
-
Coordinación de Investigación en Salud, MexicoConsejo de Ciencia y Tecnología del Estado de DurangoComplétéCarence en vitamine D | Syndrome post-COVID-19 | Longue COVID | Carence en magnésiumMexique
-
Eli Lilly and CompanyComplétéDiabète sucré de type 1Allemagne